|
The pharmaceutical exporters are set to raise a wide range of customs-related operational challenges at a high-level meeting with the commissioner of Customs at Jawaharlal Nehru Custom House (JNCH), Nhava Sheva, Mumbai, for effective trade facilitation.
The meeting, scheduled for July 7, 2026, with Giridhar G. Pai, Commissioner of Customs, is expected to provide a crucial platform for addressing procedural bottlenecks that pharma exporters and importers say are affecting the timely movement of pharmaceutical consignments through one of India's busiest maritime trade gateways.
The issues raised by pharmaceutical exporters reflect a broad spectrum of operational concerns. Industry stakeholders have reported delays in assessment and clearance of both export and import consignments, prolonged examination procedures, repeated inspections, and unwarranted procedural queries that slow down cargo movement.
Exporters have also pointed to challenges involving documentation, tariff classification, valuation disputes, shipping bill processing, amendments, factory stuffing permissions, Let Export Orders (LEO), duty drawback claims, IGST refunds and other export incentive mechanisms.
Particular concern has been expressed over the handling of temperature-sensitive pharmaceutical products, where delays in customs processes can potentially compromise product quality, regulatory compliance and delivery commitments in international markets. Given the highly regulated nature of pharmaceutical exports, timely customs clearance remains critical for maintaining product integrity and fulfilling contractual obligations with overseas buyers.
The meeting assumes significance as India continues to strengthen its position as one of the world's leading suppliers of pharmaceutical products. Efficient logistics and predictable customs procedures are considered essential for sustaining export competitiveness, reducing transaction costs and enhancing India's reputation as a reliable global supplier of medicines and healthcare products.
Officials associated with the development have emphasized that the effectiveness of the discussions will depend on the specificity of the inputs and issues received from exporters. Exporters have therefore been also requested to submit detailed instances of customs-related difficulties through a designated Form to present evidence-based representations before the Customs authorities.
The initiative highlights the collaborative approach being adopted by industry and government to identify procedural inefficiencies and develop solutions that facilitate legitimate trade while ensuring regulatory compliance. The outcome of the meeting is expected to be closely watched by pharmaceutical manufacturers, exporters, customs brokers, logistics providers, freight forwarders, shipping lines and regulatory authorities, all of whom have a direct stake in improving cargo clearance efficiency at JNCH.
With pharmaceutical exports contributing significantly to India's foreign exchange earnings and global healthcare supply chains, stakeholders expect the discussions to pave the way for streamlined customs procedures, quicker clearances and a more business-friendly trade environment at the country's premier container port.
|